Biotech Values

[DewDiligence]

Re: INFORM-1

I was a little disappointed in the higher dosing groups not appearing to have a greater impact on viral load reduction.

This is a typical outcome in a short-term, dose-escalation study. I don’t see it as a negative at all.

On the plot you posted, it’s notable how the blue line, representing ITMN-191 monotherapy on days 1-3 followed by combo therapy on days 4-7, has a saw-tooth pattern during the monotherapy period that gets smoothed out when combo treatment begins on day 4. In other words, R7128 compensates for the relatively short half-life of ITMN-191 and eliminates the intra-dose troughs.